Overview

Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth

Status:
Not yet recruiting
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
A single-center, randomized, open-label, crossover study to evaluate the pharmacokinetic drug-drug interaction and safety of the quadruple therapy with Anaprazole 20mg/Amoxicilin 1000mg/Clarithromycin 500mg/Bismuth Potassium Citrate 0.6g in healthy Chinese male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Sihuan Pharmaceutical Holdings Group Ltd.
Treatments:
Amoxicillin
Bismuth
Clarithromycin